Results 261 to 270 of about 87,108 (308)
Some of the next articles are maybe not open access.
Peptides, 2022
Apolipoprotein A1 (ApoA1), a major component of high-density lipoprotein (HDL), is a protective factor against cardiovascular disease (CVD). A recent epidemiological study found an association between neuropeptide Y (NPY) gene polymorphism and serum HDL levels. However, the direct effect of NPY on ApoA1 expression remains unknown.
Bingyang, Liu, Fu, Chen
openaire +2 more sources
Apolipoprotein A1 (ApoA1), a major component of high-density lipoprotein (HDL), is a protective factor against cardiovascular disease (CVD). A recent epidemiological study found an association between neuropeptide Y (NPY) gene polymorphism and serum HDL levels. However, the direct effect of NPY on ApoA1 expression remains unknown.
Bingyang, Liu, Fu, Chen
openaire +2 more sources
Neuropeptide Y receptor antagonists
Expert Opinion on Therapeutic Patents, 1999On the basis of pharmacological observations, neuropeptide Y (NPY) has been implicated to be involved in numerous physiological functions. Preliminary results suggest a wide therapeutic utility for NPY antagonists in disorders such as anxiety, appetite stimulation, obesity, alcohol intake, hypertension, and regulation of coronary tone. This review will
openaire +1 more source
Neuropeptide Y Y1 receptors in vascular pharmacology
European Journal of Pharmacology, 1998The existence of neurogenic mediator candidates apart from noradrenaline and acetylcholine involved in the control of vascular tone has attracted enormous attention during the past few decades. One such mediator is neuropeptide Y (NPY), which is co-localized with noradrenaline in sympathetic perivascular nerves.
A, Franco-Cereceda, J, Liska
openaire +2 more sources
Neuropeptide Y Receptor in Vascular Smooth Muscle
Journal of Neurochemistry, 1991Abstract: 125I‐Bolton‐Hunter (125I‐BH) neuropeptide Y (NPY) was used to identify specific high‐affinity NPY binding sites in porcine aortic smooth muscle membrane fractions and to characterize the binding sites in comparison with those in porcine hippocampal membrane fractions.
Y, Shigeri, S, Mihara, M, Fujimoto
openaire +2 more sources
Neuropeptide Y Receptor Subtypes, Y1 and Y2
Annals of the New York Academy of Sciences, 1990Heterogeneity among NPY (and PYY) receptors was first proposed on the basis of studies on sympathetic neuroeffector junctions, where NPY (and PYY) can exert three types of action: 1) a direct (e.g., vasoconstrictor) response; 2) a postjunctional potentiating effect on NE-evoked vasoconstriction; and 3) a prejunctional suppression of stimulated NE ...
C, Wahlestedt +6 more
openaire +2 more sources
Novel non-peptidic neuropeptide Y Y 2 receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2004Through SAR studies of a piperidinylindoline cinnamide HTS lead, the first potent, non-peptide, low molecular weight selective Neuropeptide Y Y2 (NPY Y2) antagonists have been synthesized. The SAR studies around the piperidinyl, the indolinyl, and the cinnamyl moieties are discussed.
Jill A, Jablonowski +10 more
openaire +2 more sources
Effect of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246 on neuropeptide Y release
European Journal of Pharmacology, 2000We have examined the selective neuropeptide Y Y(2) receptor antagonist, (S)-N(2)-[[1-[2-[4-[(R,S)-5,11-dihydro-6(6h)-oxodibenz[b, e]azepin-11-yl]-1-piperazinyl]-2-oxoethyl]cyclopentyl]acetyl ]-N-[2-[1 ,2-dihydro-3,5(4H)-dioxo-1,2-diphenyl-3-H-1,2, 4-triazol-4-yl]ethyl]-argininamid (BIIE0246) on neuropeptide release from rat hypothalamic slices in vitro.
P J, King +3 more
openaire +2 more sources
Neuropeptide Y receptor antagonists.
IDrugs : the investigational drugs journal, 2005A review of the patent literature for neuropeptide Y (NPY) antagonists is presented for the period of January 2000 to March 2001. This review focuses on antagonists of the Y(1) and Y(5) receptor subtypes, which have been of primary interest as anti-obesity agents.
openaire +1 more source
Neuropeptide Y (NPY) Y1 Receptor Antagonists
2001Neuropeptide Y(NPY), a 36-residue peptide amide isolated originally from porcine brain, exhibits a wide spectrum of central and peripheral activities mediated by at least six receptor subtypes denoted as Y1, Y2, Y3, Y4, Y5 and Y6 [1]. Investigations to date have implicated NPY in the pathophysiology of a number of diseases including feeding disorders ...
V. C. Dhawan +6 more
openaire +1 more source